PRTK News and Press, Paratek Pharmaceuticals Inc. From 06/29/21

Paratek Pharmaceuticals (PRTK) announced that it delivered the first procurement of NUZYRA valued at ~$38M to the Biomedical Advanced Research and Development Authority ((BARDA)).BARDA is part of the Office of the Assistant Secretary for Preparedness and Response ((ASPR)) at the U.S. Dep...

BOSTON, June 29, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and for other public health threats for civilian...

Analysts Are Boosting Ratings & Targets For These Current & Former Penny Stocks Penny stocks can be some of the most exciting types of stocks in the market. Few other asset classes offer such potential to see significant returns in such a short period of time. Now, by definition...

MediciNova (MNOV) +52% on positive MN-166 data.Raven Industries (RAVN) +50% on being acquired by CNHI for $58.0 per share.Torchlight Energy Resources (TRCH) +39% after update on proposed business combination timing and date for preferred dividend.Hennessy Capital Investment Cor...

Shares of Paratek Pharmaceuticals (NASDAQ: PRTK) were sinking 10.9% as of 11:46 a.m. EDT on Wednesday. The big decline came after the company announced that it's lowering its 2021 revenue outlook by around $38 million following discussions with the Biomedical Advanced Research and D...

Gainers: Opthea (OPT) +47%, Kindred Biosciences (KIN) +45%, Aprea Therapeutics (APRE) +38%, Altimmune (ALT) +21%, BriaCell Therapeutics (BCTX) +15%.Losers: Inhibikase Therapeutics (IKT) -24%, Paratek Pharmaceuticals (PRTK) -14%,...

Paratek Pharmaceuticals (PRTK) announces the initiation of clinical trial sites for its Phase 2b study exploring the potential utility of Nuzyra (omadacycline) as a treatment for Nontuberculous Mycobacterial ((NTM)) Pulmonary Disease caused by Mycobacterium abscessus complex (MABc). The U.S.-...

-- U.S.-Based Sites Ready to Begin Enrolling Patients, Placebo-Controlled Study Evaluating NUZYRA Efficacy at 12 Weeks of Treatment -- P otential $1.0 Billion Addressable Market Opportunity in the U.S. Based on Company Estimates -- Paratek Hosting Investor Webinar wi...

Shares of Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) traded at a new 52-week high today of $11.06. So far today approximately 302,000 shares have been exchanged, as compared to an average 30-day volume of 409,000 shares. Potential upside of 21.4% exists for Paratek Pharmaceuticals Inc., ...

BOSTON, June 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gov...